Your browser is no longer supported. Please, upgrade your browser.
Lipocine Inc.
Index- P/E- EPS (ttm)-0.25 Insider Own2.51% Shs Outstand88.29M Perf Week7.62%
Market Cap100.71M Forward P/E5.79 EPS next Y0.20 Insider Trans0.00% Shs Float86.08M Perf Month-0.88%
Income-19.00M PEG- EPS next Q-0.04 Inst Own10.40% Short Float4.54% Perf Quarter-11.02%
Sales- P/S- EPS this Y25.10% Inst Trans- Short Ratio4.79 Perf Half Y-18.71%
Book/sh0.40 P/B2.82 EPS next Y218.80% ROA-51.40% Target Price- Perf Year-20.42%
Cash/sh0.52 P/C2.16 EPS next 5Y- ROE-70.40% 52W Range0.98 - 2.42 Perf YTD-16.91%
Dividend- P/FCF- EPS past 5Y19.40% ROI- 52W High-53.31% Beta0.43
Dividend %- Quick Ratio5.40 Sales past 5Y- Gross Margin- 52W Low15.18% ATR0.05
Employees11 Current Ratio5.40 Sales Q/Q- Oper. Margin- RSI (14)50.77 Volatility3.04% 4.53%
OptionableYes Debt/Eq0.11 EPS Q/Q39.70% Profit Margin- Rel Volume0.36 Prev Close1.14
ShortableYes LT Debt/Eq0.00 EarningsAug 05 BMO Payout- Avg Volume814.80K Price1.13
Recom1.70 SMA204.18% SMA50-8.18% SMA200-21.27% Volume297,376 Change-0.88%
Jun-24-21Initiated Cantor Fitzgerald Overweight $3
Dec-10-20Upgrade Ladenburg Thalmann Neutral → Buy $3
Jan-12-18Reiterated H.C. Wainwright Buy $10 → $3
Jan-11-18Downgrade Canaccord Genuity Buy → Hold $11 → $2
Dec-08-17Resumed H.C. Wainwright Buy $10
Oct-07-16Initiated H.C. Wainwright Buy $25
Jul-22-15Initiated ROTH Capital Buy $36
Jun-23-15Initiated Canaccord Genuity Buy $15
Oct-05-21 08:00AM  
Sep-28-21 08:00AM  
Sep-20-21 08:00AM  
Sep-01-21 08:00AM  
Aug-31-21 05:43AM  
Aug-25-21 06:30AM  
Aug-09-21 07:12AM  
Aug-05-21 08:00AM  
Jul-15-21 09:00AM  
Jul-14-21 04:00PM  
Jul-06-21 08:00AM  
Jun-23-21 08:00AM  
Jun-16-21 08:00AM  
Jun-14-21 08:00AM  
Jun-07-21 08:00AM  
May-27-21 05:31AM  
May-26-21 12:44PM  
May-25-21 08:32PM  
May-24-21 05:40AM  
May-19-21 05:04AM  
May-06-21 08:00AM  
Mar-22-21 08:41AM  
Mar-11-21 08:00AM  
Mar-04-21 08:00AM  
Mar-03-21 08:00AM  
Feb-26-21 08:00AM  
Jan-28-21 04:00PM  
Jan-26-21 09:00AM  
Jan-25-21 04:00PM  
Jan-19-21 01:45PM  
Jan-14-21 08:11AM  
Jan-12-21 08:00AM  
Jan-04-21 08:00AM  
Dec-30-20 08:00AM  
Dec-29-20 08:00AM  
Dec-15-20 07:25AM  
Dec-08-20 08:48PM  
Dec-04-20 05:45PM  
Nov-30-20 06:00AM  
Nov-26-20 08:04PM  
Nov-24-20 01:53AM  
Nov-10-20 08:00AM  
Nov-06-20 08:00AM  
Nov-05-20 08:00AM  
Oct-14-20 08:00AM  
Sep-29-20 08:00AM  
Sep-21-20 08:00AM  
Sep-08-20 08:00AM  
Aug-28-20 04:00PM  
Aug-26-20 01:46PM  
Aug-25-20 07:48AM  
Aug-23-20 08:20AM  
Aug-19-20 07:56PM  
Jul-13-20 08:00AM  
May-28-20 01:58PM  
May-15-20 08:00AM  
May-13-20 08:00AM  
May-07-20 08:00AM  
May-05-20 08:00AM  
Apr-17-20 08:00AM  
Apr-10-20 08:16AM  
Apr-09-20 08:00AM  
Apr-06-20 06:00AM  
Mar-26-20 08:00AM  
Mar-13-20 08:00AM  
Mar-04-20 08:00AM  
Feb-25-20 12:07PM  
Feb-24-20 06:59AM  
Feb-11-20 04:26PM  
Jan-14-20 12:36PM  
Jan-13-20 07:35PM  
Jan-11-20 12:00PM  
Jan-10-20 08:35AM  
Jan-09-20 10:22AM  
Jan-08-20 07:26PM  
Jan-07-20 12:45PM  
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of metabolic and endocrine disorders. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase II Clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis (NASH); TLANDO XR, an oral prodrug of testosterone for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, an oral prodrug of bioidentical testosterone that has completed phase I clinical trial for the treatment of NASH cirrhosis; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Higuchi John W.DirectorDec 31Sale1.356,7009,054693,548Jan 04 02:09 PM
BROWN MORGAN REVP and CFODec 16Option Exercise0.0028,1250202,941Dec 17 04:05 PM
Patel Mahesh V.Chief Executive OfficerDec 16Option Exercise0.0045,00001,243,090Dec 17 04:06 PM
HILL STEPHEN ADirectorDec 16Option Exercise0.007,500012,750Dec 17 04:06 PM
Fink Jeffrey ArvinDirectorDec 16Option Exercise0.005,62506,562Dec 17 04:07 PM
Ono Richard DanaDirectorDec 16Option Exercise0.005,250010,125Dec 17 04:07 PM
Higuchi John W.DirectorDec 16Option Exercise0.003,7500700,248Dec 17 04:07 PM
Patel Mahesh V.Chief Executive OfficerDec 16Sale1.3515,00020,2501,228,090Dec 17 04:06 PM
BROWN MORGAN REVP and CFODec 16Sale1.358,43711,390194,504Dec 17 04:05 PM
Patel Mahesh V.Chief Executive OfficerDec 05Option Exercise0.00122,97801,198,090Dec 08 04:50 PM
BROWN MORGAN RChief Financial OfficerDec 05Option Exercise0.0070,7540174,816Dec 08 04:50 PM
Patel Mahesh V.Chief Executive OfficerDec 04Option Exercise0.00145,00001,118,612Dec 08 04:50 PM
BROWN MORGAN RChief Financial OfficerDec 04Option Exercise0.0057,5000121,312Dec 08 04:50 PM
Patel Mahesh V.Chief Executive OfficerDec 04Sale1.5743,50068,1341,075,112Dec 08 04:50 PM
BROWN MORGAN RChief Financial OfficerDec 04Sale1.5717,25027,024104,062Dec 08 04:50 PM